Durable scar size reduction due to allogeneic mesenchymal stem cell therapy regulates whole-chamber remodeling

Adam R. Williams, Viky Y. Suncion, Frederic McCall, Danny Guerra, Jacques Mather, Juan P. Zambrano, Alan W. Heldman, Joshua M. Hare

Research output: Contribution to journalArticlepeer-review


Background-Intramyocardial injection of mesenchymal stem cells (MSCs) in chronic ischemic cardiomyopathy is associated with reverse remodeling in experimental models and humans. Here, we tested the hypothesis that allogeneic MSC therapy drives ventricular remodeling by producing durable and progressive scar size reduction in ischemic cardiomyopathy. Methods and Results-Gottingen swine (n=12) underwent left anterior descending coronary artery myocardial infarction (MI), and 3 months post-MI animals received either intramyocardial allogeneic MSC injection (200 mol/L cells; n=6) or left ventricle (LV) catheterization without injection (n=6). Swine were followed with serial cardiac magnetic resonance imaging for 9 months to assess structural and functional changes of the LV. Intramyocardial injection was performed using an integrated imaging platform combining electroanatomical mapping unipolar voltage and 3-dimensional cardiac magnetic resonance imaging angiography- derived anatomy to accurately target infarct border zone injections. MSC-treated animals had a 19.62±2.86% reduction in scar size at 3 months postinjection, which progressed to 28.09 ±2.31% from 3 to 6 months postinjection (P

Original languageEnglish (US)
Article numbere000140
JournalJournal of the American Heart Association
Issue number3
StatePublished - 2013
Externally publishedYes


  • Cardiac magnetic resonance imaging
  • Ischemic cardiomyopathy
  • Stem cell therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Durable scar size reduction due to allogeneic mesenchymal stem cell therapy regulates whole-chamber remodeling'. Together they form a unique fingerprint.

Cite this